We evaluate variants of a commonly used data safety monitoring guideline in clinical trials in multiple sclerosis (MS) that flags patients who, at a follow-up visit, have 5 or more contrast-enhancing lesions (CELs) above their baseline count.
also assess if meeting the guideline on a given scan is associated with an increased risk of relapse in the subsequent 28 days. Furthermore, we explore how the results change as the threshold varies from 1 to 10 lesions above baseline. We also investigate the guideline based on meeting the threshold on 2 consecutive scans.
METHODS Patient selection. We analyze patient cohorts from 2 phase II clinical trials that failed to meet their primary outcome: one consists primarily of patients with relapsingremitting MS (RRMS), while the other consists solely of patients with secondary progressive MS (SPMS). We assess which trends persist across the cohorts and which trends may be artifacts of the specific patient group.
Description of the relapsing cohort. A total of 168 patients were randomly assigned to 1 of 4 treatment arms: low, medium, or high dose of lenercept (tumor necrosis factor blocker) or placebo. One patient withdrew after baseline, for a total of 167 patients receiving treatment and follow-up. Patients were between the ages of 18 and 55 years with Expanded Disability Status Scale (EDSS) scores less than 6. Most of the cohort had RRMS, with only 17% having SPMS. All patients had at least 2 relapses in the preceding 2 years.
Eight MRI visits were planned and took place roughly every 4 weeks starting at screening. Ten clinical assessments also occurred: one at screening, another at baseline, on a 4-week basis thereafter for 24 weeks, and on an 8-week basis thereafter for another 16 weeks. An interim analysis took place after all patients received at least 24 weeks of treatment. As a significant increase in the relapse rate among treated patients was noted, the study was stopped at the sponsor's request. Further details of this study are described in a previous publication. 5 Description of the SPMS cohort. A total of 194 patients with SPMS were randomized to receive low or high dose of micellar paclitaxel or placebo. Four patients did not start treatment, leaving 190 patients in the study. These patients were between the ages of 18 and 65, with baseline EDSS scores ranging between 3.0 and 6.5. Unlike the relapsing cohort, the protocol had no specific criterion for prestudy relapses. MRI scans were performed at 4 weeks prior to treatment, at baseline, and every 4 weeks thereafter for 24 weeks. Clinical assessments also occurred every fourth week until week 24 and an additional visit occurred at week 32. There were no safety concerns during the trial. More background information can be found in a previous article. 6
Exclusion criteria for our analysis. Patients were excluded if they had no MRI assessments after baseline. Additionally, patient visits were excluded if there was no follow-up to allow for determination of impending relapses (i.e., relapses which occur within 28 days of a visit). For example, the last MRI visit for patients who were lost to follow-up was excluded.
Standard protocol approvals, registrations, and patient consents. This study was approved by the University of British
Columbia Clinical Research Ethical Board. We performed post hoc analysis of 2 completed clinical trials. All patients gave written informed consent for the original studies.
Statistical analyses. The analysis is conducted separately for the 2 cohorts and for each threshold level. Characteristics of patients who met the guideline on at least 1 scan and those who never did are compared using Pearson 2 test, Fisher exact test, or the Wilcoxon rank sum test.
More comprehensive examination of the relationship between the probability of meeting the threshold and patient characteristics is based on overdispersed binomial regression, 7 where the patient's probability of meeting the threshold on a scan is related to patient characteristics through the log-odds using the logit function.
We are interested in whether the inclusion of an indicator of patients meeting the threshold increases the predictive value of a model that already incorporates other predictive characteristics. To investigate this, we first fit a logistic model that relates the probability of relapse within 28 days of a visit to potential predictors. The characteristics considered include the following:
• For both cohorts: baseline CEL count, gender, baseline EDSS, number of relapses in the past 2 years, T2 lesion burden (on the log scale), and time of visit (as a linear predictor) • For the relapsing cohort only: age at baseline (MS durations are unknown) • For the secondary progressive cohort only: age at MS onset, RRMS duration, and SPMS duration (as linear predictors)
We identify which characteristics are risk factors for relapse using a backward selection procedure based on the Akaike information criterion. The model incorporating the predictive covariates is then expanded to include a patient-specific random effect 8 and the threshold guideline is added. A significant adjusted odds ratio (OR) associated with the guideline indicates that the guideline accounts for a portion of the risk of relapse that is unexplained by other factors.
All analyses are conducted in the R statistical computing environment. The glm function is used to fit the binomial model with overdispersion and the logistic models without random effects, the step function is used to perform the model selection, and the lmer function from the lme4 package is used to fit the models with random effects.
RESULTS
For the relapsing cohort, only 1 patient was excluded using the exclusion criteria, resulting in 167 patients and 989 patient-visits. Furthermore, 17 of the 989 patient-visits did not have CEL information recorded, so these visits were excluded from the analysis, resulting in 972 patient-visits from 167 patients.
For the secondary progressive cohort, data were collected from 190 patients with a total of 1,079 patient-visits (not including screening, baseline, or final visits). Five patients were excluded using the exclusion criteria described earlier. The resulting dataset of 185 patients, which had a total of 1,032 patient-visits, was used for the analysis.
As detailed in table 1, generally, the relapsing cohort was younger, had a shorter disease duration (all relapsing patients had MS for less than 10 years, 6 whereas the median duration was 16 years for the secondary progressive cohort), had experienced more relapses in the preceding 2 years, and had more CELs, yet lower EDSS scores and less T2 lesion burden at baseline as expected for a primarily RRMS population. As well, the proportion of women is slightly lower in the secondary progressive cohort.
Relationship between meeting the guideline and patient characteristics. For the relapsing cohort, 5.7% of scans meet the threshold of 5 lesions. The corresponding percentage is slightly lower for the second- ary progressive cohort (4.1%). Some patients meet the threshold repeatedly; 11 patients from each cohort meet the threshold on 2 consecutive scans. Further examination by treatment group shows no difference in the proportion of patients that meet the guideline across treatment groups for the secondary progressive cohort while differences among the placebo and treated patients are seen for the relapsing cohort, in which the trial was halted due to safety concerns: only 1.2% of scans from the placebo patients of this cohort met the threshold, while the corresponding percentages for the treatment groups ranged from 4.6% to 11.5% (table e-1 on the Neurology ® Web site at www.neurology.org).
Comparisons of baseline characteristics between those who meet the threshold of 5 and those who do not are reported in table 1. For both cohorts, those who meet the threshold have clearly higher baseline CEL levels ( p Ͻ 0.0001) and T2 lesion burdens ( p Ͻ 0.003), as well as more prestudy relapses ( p: relapsing ϭ 0.09; secondary progressive ϭ 0.02). There is no gender difference across subgroups in either cohort. In the secondary progressive cohort, those who meet the threshold are younger ( p ϭ 0.02) and have higher EDSS scores ( p ϭ 0.03) but there are no such differences in the relapsing cohort.
In the assessment of the simultaneous influence of the baseline characteristics on the probability of meeting the guideline using overdispersed binomial regression, baseline CEL and T2 lesion burden remain significant for both cohorts ( p: baseline CEL Ͻ 0.03; T2 lesion burden Ͻ 0.002). Patients with higher baseline CEL counts and higher T2 lesion burden tend to meet the guideline more often. The differences across treatment groups in the re-lapsing cohort remain after adjustment for other predictors ( p ϭ 0.008).
Examination of the relationship between baseline CEL count and meeting the threshold reveals a consistent trend across thresholds of an increased chance of meeting the threshold for higher baseline CEL levels (table 2) .
Relationship between meeting the guideline and relapse rate. For the relapsing cohort, 97 relapses (in 79 patients) occurred within 28 days of an MRI scan, giving an average relapse rate of 10.0% per patientvisit. Initial examination of the frequency of relapse according to whether the threshold of 5 is met leads to an elevated overall crude OR for both cohorts (table 3). There was a steadily increasing trend in the crude ORs across thresholds 1 through 7 (table 4 and the figure). Without adjustment for other factors, it appears that meeting the threshold may be associated with an increased risk of relapse in the short term. However, only a small number of patient visits meet the guideline and have a relapse in the subsequent 28 days (for a threshold of 5 lesions, for example, there are only 10 such patient-visits), so these crude ORs are quite poorly determined.
The average relapse rate for the secondary progressive cohort is less than half that for the relapsing cohort, as there are 44 such relapses (in 36 patients), corresponding to an average relapse rate of 4.3% per patient-visit. These crude OR estimates also exhibit an increasing trend across the thresholds 1 through 7, but of increased magnitude in contrast to the relapsing cohort (table 4 and the figure).
While the ORs indicate the risk difference between scans that meet the threshold and those that do not, the sensitivity and specificity are also useful Table 3 Relapse rate across visits for the threshold of 5 contrast-enhancing lesions measures. Sensitivity (the true positive rate) represents the proportion of scans that meet the threshold out of all the scans that are followed by a 28-day subsequent relapse. Similarly, specificity (the false positive rate) is the proportion of scans that do not meet the threshold out of those that are not followed by an imminent relapse. Sensitivity across thresholds is quite low and decreases as the threshold increases while specificity is generally high and increases with the threshold value (table 4) .
Predictive power of the guideline assessed through logistic regression. Using the model selection procedure described earlier, time of MRI is the only predictor of importance for the relapsing cohort ( p ϭ 0.01); there is a decreasing trend in the relapse rate over the follow-up period. Three predictors of relapse rate are adjusted for with regards to the secondary progressive cohort: baseline CEL ( p ϭ 0.001), prestudy relapses ( p ϭ 0.11), and secondary progressive duration ( p ϭ 0.09). The corresponding adjusted ORs are considered for both cohorts across thresholds (table 4 and the figure) . The figure also displays the ORs for the modified criteria based on meeting the threshold on 2 consecutive scans.
The key observations follow:
• For the secondary progressive cohort, the adjusted ORs are of reduced magnitude compared to the crude ORs. • Meeting the threshold on a single scan is significant or nears significance for thresholds be-tween 5 and 8 ( p Յ 0.06) for the relapsing cohort. For the secondary progressive cohort, the threshold predictor is generally not significant. Nevertheless, the magnitude of the adjusted OR tends to increase as the threshold increases, at least up to a threshold of 7. • For both cohorts, the ORs using the guideline based on 2 consecutive scans are higher for more than half of the thresholds than the ORs based on 1 scan. However, the differences are rather small. Also, these estimates are even less precisely determined since there were fewer patients meeting the modified guideline.
Sensitivity analysis. As defined by the study protocols, relapses must be at least 28 days apart. Thus, given a patient is currently experiencing a relapse, it is certain that this patient will not experience another relapse in the prespecified timeframe, so visits which occur during a relapse do not provide any predictive value to the analysis. We investigated the degree to which the strength of relationship between meeting the threshold and future relapse is increased by excluding these visits. This analysis was done only for the relapsing cohort, since the end dates of a relapse for the secondary progressive cohort are unknown. We only considered thresholds based on 3, 5, and 7 CELs. Before excluding these visits, 32% of scans that met the threshold of 5 CELs were coincident with a relapse, whereas just 13% of those that did not meet the threshold were coincident with a relapse. Once these scans were excluded, the estimated ORs be- Adjusted OR ϭ based on a logistic regression with patient-specific random effects and adjustment for risk factors; crude OR ϭ calculated using the observed frequencies, unadjusted for risk factors; one scan ϭ the guideline based on a single scan; two scans ϭ the guideline based on 2 consecutive scans. Note for secondary progressive cohort: For threshold of 10 and the guideline based on 2 consecutive scans, there was an infinite log OR due to no patients having a relapse among those who met the threshold.
came higher and are significantly above 1 across the threshold levels considered, while the p values and estimated ORs corresponding to the time of visit (the only other covariate in this model) are comparable between the original and sensitivity analyses (data not shown).
DISCUSSION
Our study provides information useful for DSMBs to set evidence-based guidelines using CEL data. The results suggest that there is a positive association between meeting the guideline and risk of relapse. In both cohorts, the overall relapse rate among patients who meet the guideline is more than double that of patients who do not meet the guideline. After adjustment for other risk factors, the ORs remain above 1 but the magnitude for the secondary progressive cohort is reduced. As well, safety concerns with the relapsing cohort are indicated by differential rates of meeting the guideline across treatment arms. The precision of our analysis is limited by the relapse rate and the numbers of patients meeting the guideline, even though the cohorts investigated are large relative to other MS clinical trial cohorts. However, absence of evidence of an effect should not be interpreted as evidence of absence of that effect 9 ; the estimated size of the ORs remains informative.
Our results suggest that thresholds in the vicinity of 5-8 CELs above baseline are the best candidates for a rule of this kind. However, there is no clearcut answer regarding which threshold level is optimal; as the threshold increases, fewer patients are flagged for monitoring, decreasing the sensitivity of the guideline. Conversely, specificity increases with threshold. A desirable guideline would be highly sensitive and specific, but no such guideline has been proposed to date. As a result, careful thought about the tradeoff between sensitivity and specificity is required when choosing a threshold upon which to set a guideline based on CEL count. From the standpoint of a DSMB, it is arguable that an increase in sensitivity may be regarded as more important than the same increase in specificity. Overall, the decision of which threshold level represents the best tradeoff between sensitivity and specificity is largely related to the monitoring capacity and the level of risk thought to be tolerable by the DSMB.
The guideline is currently used to allow DSMBs to more closely monitor flagged patients-DSMBs do not necessarily alert the clinicians based on this information alone. If such a rule is to be utilized to alert clinicians of a patient's potential worsening, near real-time information from MRIs becomes crucial. In the authors' experience, a "safety read" of MRI scans to obtain CEL counts can be easily imple-mented with results sent immediately to the DSMB. These "safety reads" are performed as soon as scans are received by the reading center, and do not require the additional image preparation and processing necessary for "efficacy reads" which compute lesion volumes and identify new lesions by comparison with past scans.
We chose to investigate a relapsing and a secondary progressive cohort to assess the generalizability of the guideline across MS disease course. The underlying characteristics of these cohorts differed and differences persist in the analysis. On the individual level, we found that the chance of meeting the threshold varies greatly across baseline CEL level. Given these cohort and individual-level differences, it would be desirable to develop a guideline that depends more explicitly on patients' characteristics as well as cohort-specific characteristics. We are currently developing such an approach which takes into account patient-level variability and on-study lesion activity.
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